Catatan sumber primer
PenentuHasil topline
Verastem: Data topline Fase 3 RAMP 301 diharapkan pertengahan 2027
Presentasi korporat menyatakan bahwa uji coba Fase 3 konfirmatori RAMP 301 dari avutometinib + defactinib versus terapi pilihan investigator pada LGSOC rekuren akan melaporkan data topline pada pertengahan 2027. Pembacaan ini dimaksudkan untuk mengonfirmasi hasil RAMP 201 pada pasien KRAS-mutan dan berpotensi memperluas indikasi yang disetujui ke semua status mutasi KRAS.
Fakta utama
- Diajukan
- 8 Jan 2026, 21.16
- Peristiwa
- Hasil topline
- Arah
- Netral
- Perusahaan
VSTMVerastem- Sumber
- SEC 8-K
- Keyakinan
- Bersumber
Kutipan sumber
EX-99.1 2 tm262531d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Delivering Novel Therapies for RAS/MAPK Pathway - Driven Cancers CORPORATE PRESENTATION JANUARY 2026 2 FORWARD - LOOKING STATEMENTS This presentation includes forward - looking statements about, among other things, Verastem Oncology’s (the “Company”) programs an d product candidates, strategy, future plans and prospects, including statements related to the approval and commercialization of AVMAPKIFAKZYNJACO - PACK (avutometinib capsules; defactinib tablets) as a treatment for adult patients with K irsten rat sarcoma viral oncogene homolog (KRAS) mutant - type (mt) recurrent Low - Grade Serous Ovarian Cancer (LGSOC), the expected outcome and benefits of collaborations, including with GenFleet Therapeutics (Shanghai), Inc. (GenFlee